SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure and volatility following reports that the company is considering a multi-billion dollar equity offering to fund its aggressive AI infrastructure investments. The community is sharply divided, with some investors expressing frustration over potential share dilution and executive leadership, while others view the pullback as a buying opportunity based on the company's strong advertising fundamentals.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending as a highly divisive stock, with retail investors expressing intense frustration over long-term price underperformance despite the company's strong free cash flow and aggressive share buyback programs. Sentiment remains split between those who view the stock as a deeply undervalued, defensive 'cash machine' and others who criticize management and see it as a permanent value trap failing to keep pace with the broader tech market.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Investors in Greenwich LifeSciences are closely monitoring the latest AACR data, with sentiment driven by continued confidence in the drug's safety profile and immune response metrics despite recent volatility. Discussion is currently focused on the timeline for Phase 3 enrollment milestones, the impact of recent accounting disclosure adjustments, and the potential for a significant rerating as the company approaches interim analysis.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

The community is actively discussing Zebec Network's potential as a long-term utility play, fueled by anticipation surrounding upcoming institutional bank partnerships, the imminent release of the Super App, and legislative developments like the Clarity Act. While some retail investors express frustration over price volatility and short-term trends, many are aggressively accumulating tokens, citing strong enterprise connections and their conviction in the project's role within the future of global digital payments.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar Corp is drawing significant investor interest as a primary proxy for the upcoming SpaceX IPO, with the market focusing on the potential valuation of its large equity stake and spectrum deals. Community discussion is dominated by debates over the valuation premium of this exposure, with traders actively monitoring institutional activity and short interest for potential squeeze setups.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF (SCHD) is seeing strong investor interest as a core defensive anchor due to its quality-tilted, dividend-focused holdings. The community remains largely bullish, emphasizing long-term compounding strategies and using the fund as a hedge against broader market volatility and tech-sector uncertainty.

iShares Trust - iShares India 50 ETF

iShares India 50 ETF

The iShares India 50 ETF is trending amid significant market volatility as investors weigh aggressive economic reforms and long-term growth targets against concerns over currency weakness and geopolitical exposure. The community is actively debating the impact of foreign institutional outflows, fluctuating energy prices, and the country's attractiveness relative to other emerging markets.

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

Generate Biomedicines Inc

Generate Biomedicines is generating intense community interest following reports of a significant institutional investment, leading to polarized debates over the accuracy of these filings and the firm's long-term potential in the AI-driven drug discovery space. Investors are closely monitoring the stock's volatility and its advanced clinical pipeline while assessing whether the current price levels represent a strategic entry point or a broader market correction.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is currently attracting intense investor interest as the community weighs its aggressive Bitcoin treasury strategy and the expansion of its 'SATA' preferred stock offering against ongoing volatility in crypto markets. While some investors highlight the stock as a high-growth vehicle for Bitcoin accumulation and digital credit innovation, others express skepticism regarding the company's valuation premiums, dilution risks, and the long-term sustainability of funding treasury operations through high-interest leverage.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending following FDA approval for its xT CDx tumor-only testing platform, a catalyst that has reinforced institutional interest and spurred optimistic discussions about long-term scaling. Despite this, the community remains divided and highly active, with vocal debates surrounding the stock's high short interest, ongoing volatility, and mixed reactions to insider compensation levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors PR Newswire CAMBRIDGE, Mass., June 3, 2026 CAMBRIDGE, Mass., June 3, 2026...

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV Candidate into the Clinic

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV Candidate into the Clinic Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV Candidate into the Clinic PR Newswire CAMBRIDGE, Mass., June 1, 2026 Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new...

Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board

Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board PR Newswire NEW YORK and CAMBRIDGE, Mass., May 26, 2026 Appointment deepens...

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston PR Newswire CAMBRIDGE, Mass., April 27...

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline Decoy Therapeutics...

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 PR Newswire CAMBRIDGE, Mass. and HOUSTON, April 6, 2026 Live video webcast...

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ --Decoy Therapeutics, Inc...

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform Decoy Therapeutics Enters Strategic...

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split Decoy Therapeutics Announces 1-for-12 Reverse Stock Split PR Newswire CAMBRIDGE, Mass., March 5, 2026 CAMBRIDGE, Mass., March 5, 2026...

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Decoy Therapeutics Joins Webull Corporate Connect Service Platform Decoy Therapeutics Joins Webull Corporate Connect Service Platform PR Newswire CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 - Connect...

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. It engages in leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company was founded by Frederick E. Pierce, Barbara Hibner, Peter Marschel, Michael Lipp, and Jodi Cooper in 2020 and is headquartered in Houston, TX.

DCOYDecoy Therapeutics Inc.

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest DCOY News